-
Media ReleaseNovartis Pharmaceuticals Corporation disputes allegations in two US Government lawsuits and looks forward to a fair discussion of the facts
-
Media ReleaseFDA approves Novartis TOBI® Podhaler™ for certain cystic fibrosis patients, the first and only dry powder inhaled antibacterial in US
-
Media ReleaseNew analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies
-
Media ReleaseTV Host Phil Keoghan and Novartis team up to inspire people with MS through innovative tandem cycling campaign
-
Media ReleaseRelapsing MS patients more satisfied with Novartis oral drug Gilenya® than standard injectable therapies, according to new study results at CMSC
-
Media ReleaseNovartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and EHA
-
Media ReleaseNovartis Hosts Competition to Create Novel Mobile Solutions for Heart Failure Caregivers
-
Media ReleaseNovartis announces new data on the effects of investigational RLX030 on kidney blood flow in chronic heart failure patients
-
Media ReleaseNovartis Exelon® Patch now FDA approved to treat patients across all stages of Alzheimer's disease
-
Media ReleaseNovartis Announces FDA Approval of Xolair® (omalizumab) for Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives
-
Media ReleaseNovartis Pharmaceuticals Corporation stands behind medication adherence activities and reaffirms commitment to patient safety
-
Media ReleaseNovartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia